Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Purpura, Thrombocytopenic, Idiopathic

• A Randomized, Double-blind, Placebo-controlled, and Multi-center Clinical Study of CM313 in the Treatment of Immune Thrombocytopenia
• Teriflunomide for Steroid-resistant/Relapse Immune Thrombocytopenia
• The Combination of Teriflunomide and Danazol for Steroid-resistant/Relapse Immune Thrombocytopenia
• Teriflunomide Plus High-dose Dexamethasone as First-line Treatment in Newly Diagnosed Primary Immune Thrombocytopenia
• Anti-CD38 Antibody Treating Pediatric Primary Immune Thrombocytopenia (ITP)
• The Safety and Tolerability of STSA-1301 Subcutaneous Injection in Healthy Subjects
• A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Pediatric Primary Immune Thrombocytopenia (ITP)
• Use of Vitamin D as An Adjuvant Treatment in Children With Chronic Idiopathic Thrombocytopenic Purpura
• High-dose Dexamethasone Plus Hetrombopag vs High-dose Dexamethasone Alone as Frontline Treatment for Newly Diagnosed Adult Primary Immune Thrombocytopenia: A Prospective, Multicenter, Randomized Trial
• Immune Thrombocytopenia Management in Adults
• Low-dose Baricitinib Plus Danazol for Steroid-resistant/Relapse Immune Thrombocytopenia
• A Randomized, Double-Blind Phase 2 Study of VLX-1005 Versus Placebo in Suspected Heparin Induced Thrombocytopenia
• An Open-label Study of ALPN-303 in Subjects With Autoimmune Cytopenias
• TPO-RAs Combining Anti-CD 20 Monoclonal Antibody Versus TPO-RAs in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)
• A Prospective, One-arm and Open Clinical Study of CM313 in the Treatment of Immune Thrombocytopenia
• Extension Study of Herombopag for Pediatric Patients With Chronic Immune Thrombocytopenia
• Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)
• A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids
• IVIg Plus Low Dose rhTPO for ITP in Pregnancy
• Efficacy and Safety of QL0911 in Adult Patients With Chronic Primary Immune Thrombocytopenia: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Trial
• The Investigate Efficacy and Safety Evaluation of Bortezomib in Patients With Relapsed/Refractory Immune Thrombocytopenia
• A Randomized Trial Comparing Optimized rhTPO Treatment With Eltrombopag Treatment in Pre-treated ITP Pts
• A Clinical Trial to Assess Safety and Efficacy of Daratumumab in the Treatment of Primary Immune Thrombocytopenia
• Evaluation of the Effect in Platelet Count of Atorvastatin and N-acetyl Cysteine
• Short-course High-dose Prednisone and Dexamethasone in Children With ITP
• Two Regimens of IVIG in the Treatment of Newly Diagnosed ITP in Children
• The Combination of Terbutaline and Danazol as the Treatment of Corticosteroid-resistant/Relapse Immune Thrombocytopenia
• The Combination of Tacrolimus and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia
• Combined Steroid and Cyclosporin as First-line Treatment in Adults With Primary Immune Thrombocytopenia
• Baricitinib for Steroid-resistant/Relapse Immune Thrombocytopenia
• The Combination of ATRA and Eltrombopag as the Treatment of Steroid-resistant/Relapse ITP Based on MSC-C5b-9
• Intravenous Immunoglobulin (IVIG, Bioven) Efficacy and Safety in Chronic Primary Immune Thrombocytopenia (ITP) in Adults
• Zanubrutinib and Eltrombopag as Second-line Treatment in Adults With Primary Immune Thrombocytopenia
• The Combination of Zanubrutinib and High-dose Dexamethasone as First-line Treatment in Adult Immune Thrombocytopenia
• Evaluation of Avatrombopag for the Treatment of Thrombocytopenia in Japanese Adults With Chronic ITP
• The Combination of Sitagliptin and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia
• Efficacy and Safety of Subcutaneous Belimumab or Placebo in Addition of Rituximab in Persistent or Chronic Immune Thrombocytopenia
• The Combination of Prednisone and Recombinant Human Thrombopoietin for Treatment of Immune Thrombocytopenia in Pregnancy
• Herombopag + rhTPO in Severe Immune Thrombocytopenia
• Romiplostim Plus Dexamethasone vs Dexamethasone in Patients With Newly Diagnosed Primary Immune Thrombocytopenia
• Efficacy and Safety of TPO Receptor Agonists in the Treatment of Elderly ITP Patients
• Efficacy and Safety of Iguratimod in the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia
• The Combination of Iguratimod and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia
• A Study of Zanubrutinib in Patients With ITP
• A Study to Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Immune Thrombocytopenia
• A Prospective, One-arm and Open Clinical Study of Zanubrutinib in the Treatment of Immune Thrombocytopenia
• A Study of Orelabrutinib in Patients With ITP
• Basket Study to Assess Efficacy, Safety and PK of Iptacopan (LNP023) in Autoimmune Benign Hematological Disorders
• Open-Label Study to Evaluate the Safety and Efficacy of Avatrombopag and Remission Rates in Adults With ITP of ≤6 Months
• Phase III Study on HMPL-523 for Treatment of ITP
• A Multicenter Randomized Open-label Study of Diammonium Glycyrrhizinate Enteric-coated Capsule Plus DXM Versus DXM in Treatment of ITP
• A Clinical Trial of the Orelabrutinib in the Management of Refractory ITP
• Avatrombopag in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies
• IgIV Plus Prednisone vs High-dose Dexamethasone for ITP
• Eltrombopag Combined With Low-dose Rituximab in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies
• ASPirin in Immune thRombocytopenia Patients With Cardiovascular disEase
• Avatrombopag in Primary Immune Thrombocytopenia (ITP) in Adults
• Immunomodulation With Eltrombopag in ITP
• The Combination of Tacrolimus and High-dose Dexamethasone as First-line Treatment in Adult Immune Thrombocytopenia
• Post IVIG Medication in Children With Immune Thrombocytopenia
• Hetrombopag for Pediatric Patients With Chronic Immune Thrombocytopenia
• A Phase 2a Study Evaluating BIVV020 in Adults With Persistent/Chronic Immune Thrombocytopenia (ITP)
• Open-label Study Measuring Safety and Treatment Satisfaction in Adult Subjects With Chronic Immune Thrombocytopenia (ITP) After Switching to Avatrombopag From Eltrombopag or Romiplostim
• A Study of ATRA in the Treatment of ITP
• A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)
• Romiplostim, Rituximab and Dexamethasone as Frontline Treatment for Immune Thrombocytopenia
• Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)
• Fixed Low-dose Eltrombopag and rhTPO for Immune Thrombocytopenia (FLOWER)
• Eltrombopag Combining Rituximab Versus Eltrombopag in the Management of Primary Immune Thrombocytopenia (ITP) in Adults
• Avatrombopag for the Treatment of Thrombocytopenia in Pediatric Subjects With Immune Thrombocytopenia for ≥6 Months
• Eltrombopag Plus rhTPO Versus Eltrombopag for ITP During the COVID-19 Pandemic (ELABORATE-19)
• The Combination of Terbutaline and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia
• A Clinical Study on the Efficacy and Safety of HBM9161 in Patients With ITP
• The Combination of High-dose Dexamethasone and Acetylcysteine as the Treatment of Newly-diagnosed ITP
• A Study to Assess Efficacy and Safety of Eltrombopag in Combination With a Short Course of Dexamethasone in Patients With Newly Diagnosed ITP
• Dose Dense Rituximab for High Risk Newly Diagnosed Acute Immune Thrombocytopenic Purpura
• Phase II Trial of Romiplostim With Danazol in Patients With Eltrombopag-resistant Immune Thrombocytopenia
• A Study of TAK-079 in Adults With Persistent/Chronic Primary Immune Thrombocytopenia
• A Study to Assess the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)
• The Combination of ATRA and High-dose Dexamethasone as First-line Treatment in Adult Immune Thrombocytopenia
• A Study to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)
• A Clinical Study in Patients With Chronic Idiopathic Thrombocytopenic Purpura in R788
• Eltrombopag in Chronic ITP
• A Multicenter Randomized Study of Vitamin D Combined With HD-DXM Versus HD-DXM for the Treatment of ITP
• Evaluating the Efficacy and Safety of Different Human Thrombopoietin (rhTPO) Regimens in the Treatment of Patients With Primary Immune Thrombocytopenia (ITP)
• Single-dose Anti-CD20 Antibody With Bortezomib for Relapsed Refractory Autoimmune Hemolytic Anemia
• Study of Oral SKI-O-703, SYK Inhibitor, in Patients With Persistent and Chronic Immune Thrombocytopenia (ITP)
• A Phase 2 Study to Evaluate the Safety and Efficacy of KZR-616 in Patients With AIHA and ITP
• Glycyrrhetinic Acid Combined With Dexamethasone in Management of Newly Diagnosed ITP
• Efficacy and Safety of Ixazomib and Dexamethasone Refractory Autoimmune Cytopenia
• The Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-523 in Immune Thrombocytopenia Patients
• Eltrombopag vs Standard Front Line Management for Newly Diagnosed Immune Thrombocytopenia (ITP) in Children
• Safety and Tolerability of M254 in Healthy Volunteers and Immune Thrombocytopenic Purpura (ITP) Patients
• Safety and Efficacy of Eltrombopag Plus Pulsed Dexamethasone for Subjects With Idiopathic Thrombocytopenic Purpura
• Efficacy and Safety of rhTPO and Eltrombopag in Patients With Primary Immune Thrombocytopenia (ITP)
• Atorvastatin in Management of Newly Diagnosed ITP
• A Study to Evaluate Different Intervals Between Dosing and Feeding on the Pharmacokinetics
• A Study to Assess the Ability of Eltrombopag to Induce Sustained Remission in Subjects With ITP
• Proof-of-Concept: A Pilot, Randomized, Double-Blind Study of Oseltamivir Versus Placebo for Immune Thrombocytopenia
• Recombinant Human Thrombopoietin(rhTPO) in Pregnancy With Immune Thrombocytopenia
• The Combination of Atorvastatin, Acetylcysteine and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia
• Rituximab Combining Bortezomib Versus Rituximab in Management of ITP
• The Effect of Eltrombopag on the Expression of Platelet Collagen Receptor GPVI in Pediatric ITP.
• A Study of PRN1008 in Adult Patients With Immune Thrombocytopenia (ITP)
• The Combination of Low-dose Rituximab and ATRA as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia
• A First in HumanTrial to Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-06755347
• A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple- Dose BIVV009 in Participants With Chronic Immune Thrombocytopenia (ITP)
• The Study of Different Dose Rituximab in the Treatment of ITP
• Decitabine Combining Dexamethasone Versus Dexamethasone in Management of ITP
• Reposition of Second Line Treatment in Chronic Immune Thrombocytopenia
• Multicentre, Randomised Phase III Study of the Efficacy and Safety of Hetrombopag Olamine in Idiopathic Thrombocytopenic Purpura (ITP) Patient
• The Efficacy and Safety of Huaiqihuang Granule in Children With Chronic Primary Immune Thrombocytopenia
• H. Pylori Eradication for Moderate ITP
• Effects of Helicobacter Pylori Eradication in Children With Chronic Immune Thrombocytopenic Purpura
• Newly Diagnosed Immune Thrombocytopenia Testing the Standard Steroid Treatment Against Combined Steroid & Mycophenolate
• Efficacy and Safety Assessment of a Treatment Combining Rituximab and Belimumab in Adults With Persistent Immune Thrombocytopenia
• A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With ITP
• Clinical Trial of Gut Microbiota in the Management of Immune Thrombocytopenia
• A Single-center Clinical Trial of Bortezomib in Management of Immune Thrombocytopenia (ITP)
• The PROLONG Trial - Rituximab Maintenance Therapy in ITP
• Therapy of Adults Affected by Idiopathic Thrombocytopenic Purpura With Dexamethasone
• Association of FcγRIIIA Polymorphism and THPO Expression With Response to Eltrombopag in Refractory ITP Patients
• Efficacy and Safety of Romiplostim in Adult Subjects With Persistent or Chronic Immune Thrombocytopenia (ITP)
• Evaluating the Pharmacokinetics and Pharmacodynamics of Romiplostim in Patients With Immune Thrombocytopenia (ITP)
• DEX Combined With RTX, CSA and IVIG in the Management of Newly Diagnosed ITP Patients
• Rituximab, Eltrombopag and Dexamethasone as Frontline Treatment for Immune Thrombocytopenia
• Immunomodulation With Romiplostim in Young Adults With ITP
• Treatment of ITP With Rituximab and / or Accutane
• Thrombocytopenia in Gestational Period
• Study to Evaluate Safety, Tolerability and Efficacy of UCB7665 in Subjects With Primary Immune Thrombocytopenia
• Rituximab and Dexamethasone Followed by Mycophenolate Mofetil or Placebo in Patients With Immune Thrombocytopenia
• Different Cycles of High-dose Dexamethasone for Initial Management of Primary Immune Thrombocytopenia (ITP)
• Efficacy and Safety of DAPSone as a Second-line Option in Adult Immune Thrombocytopenia
• Safety and Efficacy Study of Hetrombopag Olamine in Chronic Idiopathic Thrombocytopenic Purpura (ITP) Patients
• PRTX-100-203 Open-Label, Dose Escalation Study in Adult Patients With ITP
• Caffeic Acid Combining High-dose Dexamethasone in Management of ITP
• A Study of Hetrombopag Olamine in Chronic Idiopathic Thrombocytopenic Purpura (ITP) Patients
• Eltrombopag in Second Line Adult Primary Immune Thrombosytopenia
• PRTX-100-202 Open-Label, Dose Escalation Study in Adult Patients With ITP
• A Multicenter Study on Recombinant Human Thrombopoietin in Management of ITP in Pregnancy
• Caffeic Acid Tablets as a Second-line Therapy for ITP
• An Observational Study to Evaluate the Efficacy of Biweekly Romiplostim in Adult Patients With ITP
• Daily Prednisone Versus Pulsed Dexamethasone in Treatment-naïve Adult Patients With Immune Thrombocytopenia
• Response Rate and Duration After Discontinuation Thrombopoietin Receptor Agonists Primary Immune Thrombocytopenia
• Drug-drug Interaction Study of Eltrombopag and Cyclosporine in Healthy Subjects
• Long-term Study of Romiplostim in Thrombocytopenic Pediatric Patients With Immune Thrombocytopenia (ITP)
• Study to Evaluate Safety and Efficacy in Adult Subjects With ITP
• Recombinant Human Thrombopoietin (rhTPO) in Management of Immune Thrombocytopenia (ITP) in Pregnancy
• A Multicenter Investigation of Recombinant Human Thrombopoietin (rhTPO) Combining Cyclosporin A Versus Cyclosporin A in Management of Steroid-Resistant/Relapsed Immune Thrombocytopenia （ITP）
• A Long-term Safety Study of Eltrombopag in Pediatric Patients With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
• An Investigation of Dexamethasone With Different Doses in the Management of Immune Thrombocytopenia (ITP)
• An Investigation of rhTPO With Different Frequencies in the Management of ITP
• A Multicentre Investigation of 2 Cycles Rituximab Compared With Standard Regimen in Management of Steroid-Resistant/Relapsed Immune Thrombocytopenia （ITP）
• Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)
• A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)
• A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)
• An Open Phase 3 Study of IV-Globulin SN Inj.10% to Treat Immune Thrombocytopenia
• Multiple Rising Does Study (Subcutaneous Doses) of BI 655064 in Male and Female Patients With Chronic Primary Immune Thrombocytopenic Purpura (ITP).
• Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases
• High-dose Dexamethasone Combining Thalidomide Versus Dexamethasone Mono-therapy for Management of Newly-diagnosed ITP
• ICON1: Treatment Decisions and Outcomes in Pediatric Refractory ITP
• A Multicenter Randomized Open-label Study of Oseltamivir Combined With HD-DEX Versus HD-DEX in the Management of ITP
• Single Rising Dose Study of MK-8723 in Healthy Participants and Participants With Immune Thrombocytopenia Purpura (MK-8723-001)
• All-Trans Retinoic Acid (ATRA) Combining Dexamethasone Versus High-dose Dexamethasone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)
• Safety and Efficacy of Eltrombopag at Escalated Doses
• Efficacy and Safety Study of Maintenance Treatment With rhTPO in Thrombocytopenic Subjects With ITP
• Oxidant Status and Effect of Antioxidant in Immune Thrombocytopenia
• Eltrombopag Phase III Study In Chinese Chronic ITP Patients
• Recombinant Human Thrombopoietin (rhTPO) Combining Rituximab Versus High-dose Dexamethasone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)
• rhTPO Combining Dexamethasone Versus High-dose Dexamethasone for Initial Treatment of ITP
• Helicobacter Pylori Treatment in Immune Thrombocytopenic Purpura (ITP) Patients
• Low-dose Rituximab Regimens in Chinese Adult Patients With Immune Thrombocytopenia
• Clinical Trial of Rituximab in Children and Adolescents With Chronic Idiopathic Thrombocytopenic Purpura (ITP)
• Efficacy of Rapamycin Therapy With Chronic Immune Thrombocytopenia
• Efficacy of Immunomudulatory Therapy With All-trans Retinoid Acid for Adults With Chronic Immune Thrombocytopenia
• The Combination of ATRA and Danazol as Second-line Treatment in Adult Immune Thrombocytopenia
• Eltrombopag and High-dose Dexamethasone as First Line Treatment for IT
• A Trial of Eltrombopag or Intravenous Immune Globulin Before Surgery for Immune Thrombocytopenia Patients
• Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs)
• A Multi-center Study of Low-dose Decitabine for the Treatment of Immune Thrombocytopenia
• A Study in Healthy Subjects to Evaluate Bioavailability of 4 Formulations of E5501
• rhTPO Combining Rituximab Versus Low-dose Rituximab in Management of ITP
• Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body.
• Recombinant Human Thrombopoietin in Combination With Rituximab in Immune Thrombocytopenia (ITP)
• Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients
• A Study to Investigate Belimumab for the Treatment of Chronic Immune Thrombocytopenia.
• Efficacy and Safety of Oral E5501 Plus Standard of Care for the Treatment of Thrombocytopenia in Adults With Chronic Immune Thrombocytopenia (Amendment 02)
• Pharmacokinetic and Pharmacodynamic Study in Healthy Subjects Comparing the Interactions Between E5501 and Verapamil and Cyclosporine.
• A Phase 3, Multicenter, Randomized, Double-blind,Active-controlled, Parallel-group Trial With an Open-labelExtension Phase to Evaluate the Efficacy and Safety of OralE5501 Versus Eltrombopag, in Adults With Chronic ImmuneThrombocytopenia (Idiopathic
• Drug Use Investigation for REVOLADE (ITP)
• High-dose Dexamethasone Versus Conventional Dose Prednisone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)
• Efficacy and Safety of Immunoglobulin Intravenous (Human) 10% (NewGam) in Primary Immune Thrombocytopenia
• Subject Variability in Two Lots of E5501 Administered to Fed and Fasted Healthy Subjects
• Recombinant Human Interleukin-11 Combination Low-dose Rituximab in Immune Thrombocytopenia
• A Study to Evaluate the Relative Bioavailability and Intra-Subject Variability of Two Lots of E5501 40 mg Tablets Administered Twice as Single Oral Doses to Healthy Subjects
• The Role of Traditional Chinese Medicine in the Treatment of Chronic Childhood Immune Thrombocytopenia (ITP)
• An Open-label Safety Study of Lusutrombopag (S-888711) in Adults With Chronic Immune Thrombocytopenia (ITP)
• Low-dose Rituximab and High-dose Dexamethasone as First Line Treatment for ITP
• A Longitudinal 2-year Bone Marrow Study of Eltrombopag in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
• Relative Bioavailibilty for Pediatric Powder for Suspension (PfOS) Formulation and Food Effect
• Promacta Pregnancy Registry
• A Study to Investigate the Efficacy and Safety of Lusutrombopag (S-888711) Tablets Administered to Adults With Immune Thrombocytopenia (ITP)
• Initial Treatment of Patients With Immune Thrombocytopenic Purpura
• The RITAI Cohort: An Observational Study on Rituximab Off-label Use for Auto-immune Disorders
• The Efficacy of Dexamethasone Versus Dexamethasone Combined With Rituximab in Patients With Newly Diagnosed Idiopathic Thrombocytopenic Purpura (ITP)
• Efficacy and Safety Study of Eltrombopag in Pediatric Patients With Thrombocytopenia From Chronic Idiopathic Thrombocytopenic Purpura (ITP)
• Eltrombopag and the Bcl-extra-large (xL) Pathway in Idiopathic Thrombocytopenic Purpura (ITP)
• Platelet Function in Idiopathic Thrombocytopenic Purpura (ITP) Patients With Eltrombopag
• Safety and Efficacy Study of PG2 to Treat Idiopathic Thrombocytopenic Purpura (ITP) Patients
• Clinical Evaluation of Eltrombopag in Chronic Idiopathic Thrombocytopenic Purpura (ITP)
• Higher Dose of Rituxan Versus Standard Doses of Rituxan With Cyclophosphamide, Vincristine, and Prednisone in Subjects With Chronic ITP
• A Study Evaluating the Addition of MabThera (Rituximab) to Standard Treatment in Patients With Idiopathic Thrombocytopenic Purpura (ITP)
• Alemtuzumab and Rituximab in the Treatment of Refractory Autoimmune Cytopenias
• Open Label Trial on the Safety and Efficacy of Sym001 in the Treatment of Immune Thrombocytopenic Purpura (ITP)
• Pilot Study of Fostamatinib Disodium/R935788 for the Treatment of Adult Refractory Immune Thrombocytopenic Purpura (ITP)
• Study In Healthy Subjects To Evaluate The Photo-Irritant Potential Of Eltrombopag
• Prednisone or Dexamethasone in Newly Diagnosed, Previously Untreated Primary Immune Thrombocytopenic Purpura
• LENS - Long-term Eltrombopag Observational Study
• Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With ChronicITP Who Completed 28 Days of Study Treatment in Protocol 501-CL-003
• Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation
• P3 Study to Evaluate Efficacy and Safety of AMG 531 in Thrombocytopenic Japanese Subjects With Immune (Idiopathic) Thrombocytopenic Purpura
• Phase I Safety and Tolerability Study of Staphylococcal Protein A in Adult Patients With Chronic ITP
• Clinical Evaluation of SB-497115-GR in Chronic Idiopathic Thrombocytopenic Purpura (ITP)
• Safety and Efficacy Study of Romiplostim (AMG 531) to Treat ITP in Pediatric Subjects
• Eltrombopag Taste Testing in Healthy Adult Volunteers
• Rituximab and Prednisone as First-Line Therapy in Treating Patients With Immune Thrombocytopenic Purpura
• A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura.
• Helicobacter Pylori Infection in Children With Chronic Idiopathic Thrombocytopenic Purpura
• High Dose Dexamethasone Vs. Conventional Dose Prednisolone in Adult ITP
• Study Of SB-497115 in Healthy Subjects and Subjects With Mild, Moderate or Severe Renal Impairment
• Study of AKR-501 Tablets Taken Orally Once Daily for 28 Days in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP)
• Clinical Study to Evaluate the Efficacy and Safety of Octagam 10% in Idiopathic Thrombocytopenic Purpura in Adults
• Repeated Exposure to Eltrombopag in Adults With Idiopathic Thrombocytopenic Purpura (REPEAT)
• Romiplostim (AMG 531) Versus Medical Standard of Care for Immune (Idiopathic) Thrombocytopenic Purpura
• Sirolimus for Autoimmune Disease of Blood Cells
• A Randomized Study of IVIG vs. IVIG With High Dose Methylprednisolone in Childhood ITP.
• Pilot Study of Rituximab for the Treatment of Acute Immune Thrombocytopenic Purpura (ITP)
• RAISE: Randomized Placebo-Controlled Idiopathic Thrombocytopenic Purpura (ITP) Study With Eltrombopag
• Ig NextGen 10% in Idiopathic Thrombocytopenic Purpura (ITP) Patients
• Study Of Eltrombopag in Healthy Subjects and Volunteers With Mild, Moderate or Severe Hepatic Impairment
• EXTEND (Eltrombopag Extended Dosing Study)
• Rituximab as Second Line Treatment for ITP
• Study of the Effectiveness of Rituximab in Adults With Chronic and Severe Immune Thrombocytopenic Purpura and Candidate for a Splenectomy
• Rapid Infusion Of Immune Globulin Intravenous (IGIV) In Patients With ITP
• Efficacy and Safety Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Adult Subjects With Chronic Idiopathic Thrombocytopenic Purpura
• A Trial to Treat Patients With ITP Who Do Not Achieve a Durable Response to Rituxan Alone
• Efficacy and Safety of IVIG-L in ITP Patients
• Treatment of Idiopathic Thrombocytopenic Purpura (ITP) With Subcutaneously Administered Anti-D
• Amgen Megakaryopoiesis Protein 2 (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP)
• Evaluating the Safety and Efficacy of Romiplostim (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP)
• Study of Doxil in the Treatment of Patients With Refractory Idiopathic Thrombocytopenic Purpura
• SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With Refractory Immune Thrombocytopenic Purpura (ITP)
• AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Prior to Splenectomy
• AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Refractory to Splenectomy
• Daclizumab to Treat Chronic Immune Thrombocytopenia
• Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases
• Phase II Study of Rituximab in Patients With Immune Thrombocytopenic Purpura
• A Phase I Study of Recombinant Human CD4 Immunoglobulin G (rCD4-lgG) in Patients With HIV-Associated Immune Thrombocytopenic Purpura